Premium
Postvaccination Morphea Profunda in a Child
Author(s) -
Khaled Aida,
Kharfi Monia,
Zaouek Anissa,
Rameh Soumaya,
Zermani Rachida,
Fazaa Becima,
Kamoun Mohamed Ridha
Publication year - 2011
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.2011.01548.x
Subject(s) - medicine , lesion , morphea , concomitant , surgery , diphtheria , methotrexate , dermatology , vaccination , pathology , lichen sclerosus
We report a new case of postvaccination morphea profunda (MP) in a child and discuss its different clinical presentations, prognosis, and therapy and its relationship with “solitary morphea profunda.” A 2‐year‐old healthy girl presented with an induration of the anterior aspect of the left thigh of 9 months duration. The lesion had appeared 3 months after a third dose of diphtheria‐tetanus‐pertussis vaccine. Cutaneous examination showed an induration of 7 × 7 cm with an “orange peel” texture after pinching the skin. Histologic examination confirmed the diagnosis of MP. Systemic steroids (1 mg/kg/day) led to the stabilization of the lesion. After 4 months of treatment, we began the concomitant use of oral methotrexate (10 mg/wk) for 2 months. Methotrexate was then continued alone for 10 months, leading to a significant regression of the induration with no relapse.